The relationship between glycated haemoglobin and blood glucose‐lowering treatment trajectories in type 2 diabetes: The Fremantle Diabetes Study Phase II
Authors' conclusion
These data demonstrate diabetes duration-dependent heterogeneity in glycaemic and treatment profiles and related clinical and laboratory variables, which have implications for management.
Study context
- Population
- Fremantle Diabetes Study Phase II participants with T2D and HbA1c and blood glucose-lowering therapy (BGLT) data over 6 years
- Participants
- 160 / 382 / 357
- Exposure
- Combined HbA1c/BGLT trajectory subgroups by diabetes duration
- Group 1n = 160
- Group 2n = 382
- Group 3n = 357
- Outcome
- Combined HbA1c/BGLT trajectory subgroups
- Follow-up
- 6 years
Methodological detailscommunity-based, group-based multi-trajectory modelling, multinomial regression
- Community-based
- Group-based multi-trajectory modelling
- Multinomial regression
Main finding
As reported in the abstract
HbA1c/BGLT trajectory subgroups
- Optimum number of trajectory subgroups: three in Group 1 (low, medium, high), four in Groups 2 and 3 (low, low/high medium, high)
- Each low subgroup maintained mean HbA1c <53 mmol/mol (<7.0%) on lifestyle measures, or monotherapy (Group 3)
- All five medium subgroups had stable HbA1c <58 mmol/mol (<7.5%) but required increasing oral BGLT, or insulin (Group 3, high medium)
- Group 1 high subgroup: falling then increasing HbA1c with steady progression to insulin
- High subgroups in Groups 2 and 3: stable HbA1c at means of ≈64 mmol/mol (8.0%) and 86 mmol/L (10.0%), respectively, on insulin
Observational data: associations, not effects.
Further findings
Baseline associates of subgroup membership
- Non-Anglo Celt ethnicity, central obesity and hypertriglyceridaemia strongly associated with Group 1 high subgroup membership
- Younger age at diagnosis and central obesity independent associates of the most adverse HbA1c trajectories in Groups 2 and 3
Original publication
The relationship between glycated haemoglobin and blood glucose‐lowering treatment trajectories in type 2 diabetes: The Fremantle Diabetes Study Phase II. Diabetes Obes Metab. Published 5 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →